Dapagliflozin antidiabetic drugs

BMS-512148 - BMS512148 - BMS 512148 - forxiga - dapagliflozin



Trial Studied treatment Control Patients Size Study type Results NCT

Diabetes type 2 - SGLT2 inhibitors in all type of patients - antidiabetic drugs in patients inadequately controlled on metformin - antidiabetic drugs in patients inadequately controlled on monotherapy - glucose lowering for cardiovascular prevention in all type of patients

Yang, 2015dapagliflozinNA NCT01095666
D1695C00001 ongoing dapagliflozindapagliflozinNA NCT02582814
Nauck, 2011dapagliflozindlipizide add on metforminNA NCT00660907
D1690C00023 ongoing dapagliflozinplaceboNA NCT02547935
DECLARE-TIMI 58 ongoing dapagliflozinplaceboNA NCT01730534
MB102-210 ongoing dapagliflozinplaceboNA NCT02383238
DERIVE ongoing dapagliflozinplaceboNA NCT02413398
DECLARE TIMI 58, 2018dapagliflozinplaceboNA Exploratory NCT01730534
D1693C00002 ongoing dapagliflozinplaceboNA NCT01257412
KohandapagliflozinplaceboNA NCT00972244
Kaku, 2014dapagliflozinplaceboNA NCT01294423
Ferrannini (MB102013), 2010dapagliflozinplaceboNA NCT00528372
Komoroski (MB102007), 2009dapagliflozinplaceboNA Exploratory NCT00162305
List (MB102008), 2009dapagliflozinplaceboNA Exploratory NCT00263276
KohandapagliflozinplaceboNA NCT00663260
KOhandapagliflozinplaceboNA Confirmatory NCT00736879
D5553C00003 ongoing dapagliflozinplacebo (add on EXE)NA NCT02229396
MB102-137 ongoing dapagliflozinplacebo (add on INS)NA NCT02096705
Wilding, 2012dapagliflozinplacebo (add on insulin)NA NCT00673231
Wilding (MB102009), 2009dapagliflozinplacebo (add on insulin)NA NCT00357370
Mathieu, 2015dapagliflozinplacebo (add on MET + SAXA)NA NCT01646320
Bailey (MB102014), 2010dapagliflozinplacebo (add on MET)NA Exploratory NCT00528879
Bolinder, 2012dapagliflozinplacebo (add on MET)NA NCT00855166
Schumm-Draeger , 2015dapagliflozinplacebo (add on MET)NA NCT01217892
Matthaei, 2015dapagliflozinplacebo (add on MET+SU)NA NCT01392677
D1683C00005 ongoing dapagliflozinplacebo (add on SAXA + MET)NA NCT02681094
Rosenstock, 2012dapagliflozinplacebo (add on TZD)NA NCT00683878
MB102-054 ongoing dapagliflozinplacebo (add-on MET)NA NCT01095653
Leiter, 2016dapagliflozinplacebo (on top standard treatment)NA NCT01042977
MB102035dapagliflozinplacebo (on top standard treatment)NA NCT00976495
Cefalu, 2015dapagliflozinplacebo (on top standard treatment)NA NCT01031680
MB102073dapagliflozinplacebo (on top standard treatment)NA NCT01137474
Weberdapagliflozinplacebo (on top standard treatment)NA NCT01195662
MB102061dapagliflozinplacebo add on DPP-4NA NCT00984867
CV181-363 ongoing dapagliflozinsaxa (add on MET)NA NCT02284893
CV181-365 ongoing dapagliflozinSaxagliptin (add on MET)NA NCT02419612
Rosenstock, 2015dapagliflozinSaxagliptin (add on MET)NA NCT01606007
0431-838 ongoing dapagliflozinSitagliptin (add on mET)NA NCT02532855
Strojek, 2011dapagliflozin + GlimepirideglimepirideNA NCT00680745
Kohandapagliflozin + merformindapagliflozinNA NCT00643851
MB102034, 2016dapagliflozin + merforminmetformin or dapaNA NCT00859898



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons